Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications.
Anti-Arrhythmia Agents
/ adverse effects
Anticoagulants
/ adverse effects
Antiviral Agents
/ adverse effects
Atrial Fibrillation
/ diagnosis
Betacoronavirus
/ drug effects
COVID-19
Coronavirus Infections
/ diagnosis
Drug Interactions
Host-Pathogen Interactions
Humans
Pandemics
Pneumonia, Viral
/ diagnosis
Risk Factors
SARS-CoV-2
Treatment Outcome
COVID-19 Drug Treatment
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
27
5
2020
medline:
28
8
2020
entrez:
27
5
2020
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) outbreak is a public health emergency of international concerns because of a highly pathogenic human coronavirus (HCoV), actually named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite much emerging data about the epidemiological association between cardiovascular diseases and COVID-19, little is still known about atrial fibrillation and its optimal management in this clinical contest. The aim of our review is to describe the pharmacological interactions between cardiovascular drugs more commonly used in atrial fibrillation management and experimental COVID-19 therapies, based on EU and US summaries of product characteristics.
Identifiants
pubmed: 32453074
doi: 10.1097/FJC.0000000000000854
pii: 00005344-202008000-00004
doi:
Substances chimiques
Anti-Arrhythmia Agents
0
Anticoagulants
0
Antiviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
138-145Commentaires et corrections
Type : CommentIn
Références
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069.
Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020;133:1025–1031.
Chen C, Chen C, Yan JT, et al. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19 [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E008.
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. doi: 10.1001/jama.2020.4683.
doi: 10.1001/jama.2020.4683
Lakkireddy DR, Chung MK, Gopinathannair R, et al. Guidance for cardiac electrophysiology during the coronavirus (COVID-19) pandemic from the heart rhythm Society COVID-19 Task Force; electrophysiology Section of the American College of Cardiology; and the Electrocardiography and arrhythmias Committee of the Council on clinical Cardiology, American Heart Association. Circulation. 2020. doi: 10.1161/CIRCULATIONAHA.120.047063.
doi: 10.1161/CIRCULATIONAHA.120.047063
Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180–1184.
Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:203–208.
Michot JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020.
Chen MC, Chang JP, Liu WH, et al. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. Am J Cardiol. 2008;102:861–865.
Wu N, Xu B, Xiang Y, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int J Cardiol. 2013;169:62–72.
Ponte ML, Keller GA, Di Girolamo G. Mechanisms of drug induced QT interval prolongation. Curr Drug Saf. 2010;5:44–53.
Roden DM, Balser JR, George AL Jr, et al. Cardiac ion channels. Annu Rev Physiol. 2002;64:431–475.
Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219–233.
Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004;15:475–495.
Fenichel RR. Development of drugs that alter ventricular repolarization. Am J Ther. 2002;9:127–139.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
Kimmel SE. Warfarin pharmacogenomics: current best evidence. J Thromb Haemost. 2015;13(suppl 1):S266–S271.
European Summaries of Product Characteristics. Available at https://www.ema.europa.eu/en. Accessed April 15.
Unites States Summaries of Product Characteristics. Available at https://www.accessdata.fda.gov/. Accessed April 15.
Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;20:1231–1242.
Boneu B, Caranobe C, Sie P. Pharmacokinetics of heparin and low molecular weight heparin. Baillieres Clin Haematol. 1990;3:531–544.
Saltiel M. Dosing low molecular weight heparins in kidney disease. J Pharm Pract. 2010;23:205–209.
Glesby MJ, Aberg JA, Kendall MA, et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther. 2005;78:143–153.
Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007;27:874–887.
Kirch W, Gorg KG. Clinical pharmacokinetics of atenolol--a review. Eur J Drug Metab Pharmacokinet. 1982;7:81–91.
Wiest DB, Haney JS. Clinical pharmacokinetics and therapeutic efficacy of esmolol. Clin Pharmacokinet. 2012;51:347–356.
Iisalo E. Clinical pharmacokinetics of digoxin. Clin Pharmacokinet. 1977;2:1–16.
Tamargo J, Capucci A, Mabo P. Safety of flecainide. Drug Saf. 2012;35:273–289.
Salerno DM, Granrud G, Sharkey P, et al. Pharmacodynamics and side effects of flecainide acetate. Clin Pharmacol Ther. 1986;40:101–107.
Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol. 2003;91:15D–26D.
Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63:769–802.
Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984;9:136–156.
Allen MJ, Nichols DJ, Oliver SD. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. Br J Clin Pharmacol. 2000;50:247–253.
Camm AJ. The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A? Curr Cardiol Rev. 2014;10:309–314.
Sahinovic MM, Struys M, Absalom AR. Clinical Pharmacokinetics and Pharmacodynamics of Propofol. Clin Pharmacokinet. 2018;57:1539–1558.
Billard V. Pharmacokinetic-pharmacodynamic Relationship of Anesthetic Drugs: From Modeling to Clinical Use. 4: F1000 Faculty Rev-1289; 2015. doi: 10.12688/f1000research.6601.1. eCollection 2015.
Kreuer S, Bruhn J, Wilhelm W, et al. Pharmacokinetic-pharmacodynamic models for inhaled anaesthetics [in German]. Anaesthesist. 2007;56:538–556.
Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008:335–360.
Cardiology ESo. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. 2020. Available at: https://www.escardio.org/static_file/Escardio/Education-General/Topic%20pages/Covid-19/ESC%20Guidance%20Document/ESC-Guidance-COVID-19-Pandemic.pdf.